Notable Research

We believe that research and clinical trials are critical elements in finding new medications and treatments to help our patients fight cancer. We have long been actively engaged in academic research and continue to participate in a variety of clinical trials. We are committed to educating our patients about the most recent medical findings, research studies and new patient therapies to help empower them to make informed decisions about their care.
Dr. McGonigle and Dr. Muntz offer their patients state-of-the-art treatment on clinical research studies, investigator-initiated studies and other studies.


  • Phase 2 Prospective Study of Weekly Topotecan and Bevacizumab in Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (OC) KF McGonigle, HG Muntz
    This study evaluates the effectiveness of a chemotherapy drug commonly used to treat patients with recurrent ovarian cancer: topotecan, with an antiangiogenesis agent, bevacizumab. Patients with platinum resistant ovarian cancer have a poor prognosis and generally respond poorly to treatment. Compared with prior studies of patients who were treated with bevacizumab or topotecan alone, results compare favorably, suggesting a potential benefit with this combination regimen.
    Dr. McGonigle is the principal investigator of this investigator-initiated study. The study, supported by Genentech and GlaxoSmithKline, is being performed in conjunction with colleagues from Puget Sound Oncology Consortium and Virginia Mason Medical Center. Dr. McGonigle presented data from this study at the Annual Meeting of the American Society of Clinical Oncology, May 2008, and Western Association of Gynecologic Oncology, June 2008. She will also be presenting the data at the Marsha Rivkin Ovarian Cancer Research Symposium in Seattle, September 2008.
  • McGonigle KF, Vsilev SA, Odom-Maryon TL, Simpson JF. Ovarian histopathology in breast cancer patients receiving tamoxifen. Gynecol Oncol 73:402-406, 1999

  • Elkas JC, Holschneider CH, Katz B, Li AJ, Pharm RL McGonigle KF, Berek JS. The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. Int J. Gynecol CA 13:138-141, 2003

  • McGonigle KF, Smith DD, Marx HF, Morgan RJ, Vasilev SA, Roy S, Morgan RJ, Wong PT, Simpson JF, Wilczynski SP. Uterine effects of tamoxifen: a prospective study. Int J Gynecol Cancer. 16 (2): 814-820, 2006

  • Morgan RJ, Synold TV, Gandara D, Muggia F, Scudder S, Reed R, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial. Int J Gynecol Cancer, 17:373-378, 2007.

  • For a full list of Dr. McGonigle’s publications, click here.


  • Phase 2 Prospective Study of Weekly Topotecan and Bevacizumab in Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (OC) KF McGonigle, HG Muntz

  • Goff BA, Mandel LS, Muntz HG, Melancom CH. Ovarian cancer diagnosis: Resuls of a national ovarian cancer survey. Cancer 2000; 89:2068-2075.

  • Muntz HG, Goff BA, McGonigle K, Isacson C. The significance of psammoma bodies in screening cervical cytology smears. Am J Obstet Gynecol. 2003; 188:1609-1614.

  • Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291:2705-2712.

  • Muntz HG, McGonigle KF, Malpass TW, Roberston MD, Kamarauskiene D, Weiden P. Phase II study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal cancer. Cancer Investigation 2006; 24: 39 – 41

  • Goff BA, Matthews BJ, Wynn M, Muntz HG, Lishner DM, Baldwin L-M. Ovarian cancer: Patterns of surgical care across the United States. Gynecologic Oncology 2006; 103:383-390.

  • For a full list of Dr. Muntz’s publications, click here.